arrow
C

Cheryl M. Corcoran

Icahn School of Medicine at Mount Sinai
H指数:55
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predicting transition to psychiatric disorders in clinical high-risk for psychosis subjects using machine learning and facial features

使用机器学习和面部特征预测精神病高风险个体的精神障碍转换

2026-09-010
OAAI
Processing Speed and Verbal Learning Ability as Predictors of Assessor-Rated and Ecological Momentary Assessment Self-Reported Functioning: Findings from AMP SCZ

处理速度和言语学习能力作为评估者评定和生态瞬时评估自报功能表现的预测因素:AMP SCZ的研究发现

2026-08-030
PRE
Local chemoarchitecture explains widespread lower cortical thickness associated with clinical high risk for psychosis

局部化学构筑解释了与精神病临床高风险相关的广泛皮质变薄现象

2026-04-040
PRE
Structural covariance network topology in individuals at clinical high risk for psychosis: the ENIGMA-CHR Study

精神分裂症临床高风险个体中的结构协方差网络拓扑:ENIGMA-CHR研究

2025-10-220
OA
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative

收集语言、语音声学和面部表情数据以预测精神分裂症及其他临床结果:AMP® SCZ倡议的策略

2025-10-150
OAAI
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

加速药品合作计划®精神分裂症项目中的脑电图协议:测量指标的可靠性与稳定性

2025-06-060
OAAI
Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program

加速药物合作®精神分裂症计划中的数字健康技术

2025-06-030
OAAI
Attenuated symptoms are associated with connectedness and emotional expression in narratives based on emotional pictures in a Brazilian clinical high-risk cohort

症状减轻与基于情绪图片的叙事中的连接感和情感表达相关,在一项巴西临床高风险队列研究中。

2025-06-010
PRE
Bridging Science and Hope: integrating and Communicating Lived experience in Accelerating Medicines Partnership® Schizophrenia Program

连接科学与希望:整合并传播在加速药物合作®精神分裂症计划中的亲身经历

2025-04-070
OA
Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program

加速药物伙伴关系®精神分裂症计划的数据分析策略

2025-04-031
OA
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program

样本确定和临床结局指标在加速药物伙伴关系®精神分裂症计划中

2025-04-031
OA
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample

加速药物伙伴关系中的认知评估®精神分裂症计划: 在不同的国际样本中协调优先事项和策略

2025-03-240
OAAI
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership—Schizophrenia

临床高风险精神病患者的大规模国际样本中,预后调整问题、阴性症状和认知障碍:来自加速药物合作计划—精神分裂症的研究结果

2025-01-010
OA
CHARACTERIZATION OF THE PRODROMAL QUESTIONNAIRE-BRIEF (PQ-B) SCREENER FOR PSYCHOSIS AND PSYCHOSIS RISK IN NYC OUTPATIENT MENTAL HEALTH SETTINGS

精神分裂症及精神分裂症风险筛查中纽约市门诊心理健康设置下的《前驱症状问卷-简版》(PQ-B)筛查工具的特征分析

2024-10-010
PRE
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

加速药物伙伴关系®精神分裂症 (AMP®SCZ): 最大的全球精神病临床高风险前瞻性队列研究的基本原理和研究设计

2024-03-0712
OAAI